They find that the pan-HER mixture of six antibodies targeting EGFR, HER2, and HER3 decreases HER family receptors in acquired CTX-resistant HNSCC cells lines and overcomes CTX resistance in PDX (98). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.